The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer

Abstract Background Decision‐making regarding adjuvant chemotherapy for early‐stage breast cancer can be guided by genomic assays such as OncotypeDX. The concordance of expected clinical decisions guided by OncotypeDX and prognostication online tools such as PREDICT is unknown. Methods We performed...

Full description

Bibliographic Details
Main Authors:	Daniel A. Goldstein, Chen Mayer, Tzippy Shochat, Daniel Reinhorn, Assaf Moore, Michal Sarfaty, Rinat Yerushalmi, Hadar Goldvaser
Format:	Article
Language:	English
Published:	Wiley 2020-07-01
Series:	Cancer Medicine
Subjects:	adjuvant breast cancer genomic assays oncotype predict tool
Online Access:	https://doi.org/10.1002/cam4.3088

Similar Items

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
by: Beate Jahn, et al.
Published: (2017-10-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
by: Yogeshkumar Malam, et al.
Published: (2022-08-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
by: Didi Feldman, et al.
Published: (2023-10-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-04-01)

A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions
by: Asma Munir, et al.
Published: (2023-01-01)

Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score<sup>®</sup> Test?
by: Francesca Galati, et al.
Published: (2022-11-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022-09-01)

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
by: Ran Song, et al.
Published: (2023-09-01)

Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score
by: Vikram R. Shaw, et al.
Published: (2023-06-01)

Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings
by: Haojia Li, et al.
Published: (2019-10-01)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
by: Matthew G. Davey, et al.
Published: (2022-07-01)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
by: Valeria Romeo, et al.
Published: (2023-03-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey
by: Vahit Özmen, et al.
Published: (2016-07-01)

Correlation analysis between mammography features of early-stage invasive breast ductal carcinoma with positive ER, negative HER2, negative lymph node and Oncotype DX21 gene assay results
by: WANG Ting , LIU Zhuang , GONG Jing , JIANG Lin , SHEN Xigang , GU Yajia
Published: (2021-06-01)

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
by: Stephane Thibodeau, et al.
Published: (2019-07-01)

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany
by: M.P. Lux, et al.
Published: (2022-01-01)

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
by: John Loggie, et al.
Published: (2024-06-01)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
by: Çağlar Ünal, et al.
Published: (2023-06-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)

Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay
by: Michael A. Jacobs, et al.
Published: (2020-09-01)

Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
by: Hongxiao Li, et al.
Published: (2022-06-01)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
by: Michael Crager, et al.
Published: (2022-11-01)

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study
by: Arif Ali Awan, et al.
Published: (2024-02-01)

Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer
by: Eoin P. Kerin, et al.
Published: (2022-12-01)

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
by: Daniel Reinhorn, et al.
Published: (2021-08-01)

The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
by: Atilla Soran, et al.
Published: (2020-04-01)

Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score
by: Abdalla Saad Abdalla Al-Zawi, et al.
Published: (2022-07-01)

P168 OncotypeDX RS new TAILORx cut-offs: omitting Chemotherapy in more patients aged >50 years with Early Breast Cancer
by: C. MarKopoulos, et al.
Published: (2023-03-01)

Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study
by: Alberto Zambelli, et al.
Published: (2020-08-01)

Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis
by: Arya Mariam Roy, et al.
Published: (2023-08-01)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
by: Ran Cheng, et al.
Published: (2020-10-01)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
by: Luca Licata, et al.
Published: (2023-06-01)

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX<sup>®</sup> Testing
by: Bradley M. Turner, et al.
Published: (2023-01-01)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
by: Alshamsan B, et al.
Published: (2021-12-01)

Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study
by: Antonio Llombart-Cussac, et al.
Published: (2023-02-01)